Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors: Frequent expression of androgen receptor in a subset of malignant salivary gland tumors

American Journal of Clinical Pathology

Volumn 119, Issue 6, 2003, Pages 801-806

  Nasser, Selim M ^a   Faquin, William C ^a   Dayal, Yogeshwar ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Androgen; Estrogen; Hormones; Progesterone; Receptors; Salivary gland

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; FORMALDEHYDE; PROGESTERONE RECEPTOR; FIXATIVE;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; SALIVARY GLAND DUCT; SALIVARY GLAND TUMOR; TISSUE FIXATION; CELL NUCLEUS; CHEMISTRY; HISTOLOGY; MIDDLE AGED; SEXUAL DEVELOPMENT;

ADENOCARCINOMA; ADENOMA, PLEOMORPHIC; ADULT; AGED; CARCINOMA, MUCOEPIDERMOID; CELL NUCLEUS; FEMALE; FIXATIVES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SALIVARY GLAND NEOPLASMS; SEX CHARACTERISTICS; TISSUE EMBEDDING;

EID: 84983143811     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/RVTP1G0Q727WJUQD     Document Type: Article

References (34)

1. Jeannon JP, Soames JV, Bell H, et al. Immunohistochemical detection of oestrogen and progesterone receptors in salivary tumours. Clin Otolaryngol. 1999;24:52-54.
2. Onitsuka T. Sex hormones in papillary carcinoma of thyroid gland and pleomorphic adenoma of parotid gland. Acta Otolaryngol. 1994;114:218-222.
3. Miller AS, Hartman GG, Chen SY, et al. Estrogen receptor assay in polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. Oral Surg Oral Med Oral Pathol. 1994;77:36-40.
4. Lamey PJ, Leake RE, Cowan SK, et al. Steroid hormone receptors in human salivary gland tumours. J Clin Pathol. 1987;40:532-534.
5. Shick PC, Riordan GP, Foss RD. Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;80:440-444.
6. Barnes L, Rao U, Contis L, et al. Salivary duct carcinoma, II: immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol. 1994;78:74-80.
7. Dimery IW, Jones LA, Verjan RP, et al. Estrogen receptors in normal salivary gland and salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 1987;113:1082-1085.
8. Lewis JE, McKinney BC, Weiland LH, et al. Salivary duct carcinoma: clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77:223-230.
9. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11:1033-1038.
10. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24:579-586.
11. Fan CY, Melhem MF, Hosal AS, et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127:1075-1079.
12. Hoang MP, Callender DL, Sola Gallego JJ, et al. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol. 2001;19:865-871.
13. Moriki T, Ueta S, Takahashi T, et al. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer. 2001;93:344-350.
14. Ellis GL, Auclair PL. Tumors of the Salivary Glands. Washington, DC: Armed Forces Institute of Pathology; 1995
15. Atlas of Tumor Pathology; Third Series, Fascicle 17.
16. Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A, et al. Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Craniomaxillofac Surg. 1997;25:328-334.
17. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer. 1993;72:1503-1512.
18. Barnes L, Rao U, Krause J, et al. Salivary duct carcinoma, I: a clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 1994;78:64-73.
19. Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol. 1996;27:561-566.
20. Skalova A, Starek, Kucerova V, et al. Salivary duct carcinoma: a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract. 2001;197:621-626.
21. Hellquist HB, Karlsson MG, Nilsson C. Salivary duct carcinoma; a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol. 1994; 172:35-44.
22. Spiro RH, Huvos AG, Strong EW. Malignant mixed tumor of salivary origin: a clinicopathologic study of 146 cases. Cancer. 1977;39:388-396.
23. Olsen KD, Lewis JE. Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck. 2001;23:705-712.
24. Muller S, Vigneswaran N, Gansler T, et al. c-erbB-2 oncoprotein expression and amplification in pleomorphic adenoma and carcinoma ex pleomorphic adenoma: relationship to prognosis. Mod Pathol. 1994;7:628-632.
25. Rosa JC, Fonseca I, Felix A, et al. Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Histopathology. 1996;28:247-252.
26. Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol. 2001;32:596-604.
27. Muller S, Barnes L. Basal cell adenocarcinoma of the salivary glands: report of seven cases and review of the literature. Cancer. 1996;78:2471-2477.
28. Ellis GL, Wiscovitch JG. Basal cell adenocarcinomas of the major salivary glands. Oral Surg Oral Med Oral Pathol. 1990;69:461-469.
29. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20:3001-3015.
30. Roy AK, Tyagi RK, Song CS, et al. Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann N Y Acad Sci. 2001;949:44-57.
31. Toda I, Wickham LA, Sullivan DA. Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice. Clin Immunol Immunopathol. 1998;77:59-71.
32. Quarmby VE, Beckman WC Jr, Wilson EM, et al. Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate. Mol Endocrinol. 1987;1:865-874.
33. Berchem GJ, Bosseler M, Sugars LY, et al. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 1995;55:735-738.
34. van der Hulst RWM, van Krieken JH, van der Kwast TH, et al. Partial remission of parotid gland carcinoma after goserelin [letter]. Lancet. 1994;344:817.